Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study
For the complete article in PDF format, please click here: full article
Objective: To incorporate a new trial design to examine clinical response, cytokine expression and joint imaging in patients with rheumatoid arthritis (RA) switching from etanercept to infliximab treatment.
Methods: A randomised, open-label, clinical trial of 28 patients with an inadequate response to etanercept was conducted. Eligible patients received background methotrexate and were randomised 1:1 to discontinue etanercept and receive infliximab 3 mg/kg at weeks 0, 2, 6, 14 and 22, or to continue etanercept 25 mg twice weekly. Data were analysed for clinical response, serum biomarker levels, radiographic progression, MRI and adverse events.
Results: At week 16, 62% of infliximab-treated patients achieved American College of Rheumatology 20% criteria for improvement in RA (ACR20) responses compared with 29% of etanercept-treated patients. A 30.8% decrease from baseline in Disease Activity Score 28 was observed in patients receiving infliximab, compared with a 16.0% decrease in patients receiving etanercept. ACR20 and American College of Rheumatology 50% criteria for improvement in RA responses correlated at least minimally with intracellular adhesion molecule-1 and interleukin 8 in patients receiving infliximab. 38% of patients who were switched to infliximab showed reductions in Health Assessment Questionnaire scores (>0.4), compared with 0% of patients receiving etanercept. MRI analyses were inconclusive. Both drugs were well tolerated; 54% of infliximab-treated patients and 50% of etanercept-treated patients reported adverse events.
Conclusions: In this exploratory, open-label trial (with single-blind evaluator), patients were randomised to continue with etanercept or switch to infliximab. The small sample size of this hypothesis-generating study was underpowered to show statistical differences between groups. There was a numerical trend favouring patients who switched to infliximab, therefore warranting further study with a more rigorous design.
This study was carried out at several centers:
Daniel E Furst 1, Norman Gaylis 2, Vance Bray 3, Ewa Olech 4, David Yocum 5, Jeffrey Ritter 6, Michael Weisman 7, Daniel J Wallace 8, John Crues 9, Dinesh Khanna 1, Gregory Eckel 10, Newman Yeilding 11, Peter Callegari 11, Sudha Visvanathan 11, Jeannie Rojas 11, Ronald Hegedus 11, Laura George 11, Khalid Mamun 11, Keith Gilmer 11, Orrin Troum 12
1 Division of Rheumatology, Department of Medicine, University of California Los Angeles, Los Angeles, California, USA
2 Infusion and Immunotherapy Center of South Florida, Aventura, Florida, USA
3 Denver Arthritis Clinic, Denver, Colorado, USA
4 Oklahoma University Health Sciences Center, Oklahoma City, Oklahoma, USA
5 University of Arizona Health Sciences Center, Tucson, Arizona, USA
6 Center for Arthritis and Rheumatology, South Miami, Florida, USA
7 Cedars-Sinai Medical Center, Division of Rheumatology, Los Angeles, California, USA
8 Wallace Rheumatic Study Center, Los Angeles, California, USA
9 Pronet Imaging, Los Angeles, California, USA
10 Department of Radiological Sciences, University of California Los Angeles, Torrance, California, USA
11 Centocor, Malvern, Pennsylvania, USA
12 Keck School of Medicine, University of Southern California, Los Angeles, California, USA